ACRUX LIMITED — Capital/Financing Update 2015

Feb 1, 2015

02 FEBRUARY 2015

ACRUX (ACR) - ASX ANNOUNCEMENT

AXIRON NET SALES FOR CALENDAR YEAR 2014

Acrux (ASX: ACR) today confirmed that Eli Lilly reported Axiron net sales of US$47.6 million in its financial results for the quarter ended 31 December 2014. Axiron net sales for the year ended 31 December 2014 totalled US$170.5m compared to US$178.7m in the year prior.

Global Axiron net sales for the 2014 calendar year are shown in the following table:

Q1 2014	Q2 2014	Q3 2014	Q4 2014	Total for 2014
US$39.5m	US$47.1m	US$36.3m	US$47.6m	US$170.5m

Axiron share of the topical testosterone market at end of 2014 was 13.7%, which has held steady despite the entry of generics to competitor products through 2014.

Contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

www.acrux.com.au

• Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology.

• The Acrux technology, used in marketed products including Axiron®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.

• Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.

==> picture [123 x 65] intentionally omitted <==

==> picture [361 x 65] intentionally omitted <==

==> picture [105 x 65] intentionally omitted <==